Anthrax protective antigen is a calcium-dependent serine protease by Storm, L. (Lisanne) et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=kvir20
Virulence
ISSN: 2150-5594 (Print) 2150-5608 (Online) Journal homepage: http://www.tandfonline.com/loi/kvir20
Anthrax protective antigen is a calcium-dependent
serine protease
Lisanne Storm, Floris J. Bikker, Kamran Nazmi, Albert G. Hulst, Debora V. der
Riet-Van Oeveren, Enno C.I. Veerman, John P. Hays & Wendy E. Kaman
To cite this article: Lisanne Storm, Floris J. Bikker, Kamran Nazmi, Albert G. Hulst, Debora V.
der Riet-Van Oeveren, Enno C.I. Veerman, John P. Hays & Wendy E. Kaman (2018) Anthrax
protective antigen is a calcium-dependent serine protease, Virulence, 9:1, 1085-1091, DOI:
10.1080/21505594.2018.1486139
To link to this article:  https://doi.org/10.1080/21505594.2018.1486139
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 27 Jul 2018.
Submit your article to this journal 
Article views: 173
View Crossmark data
BRIEF REPORT
Anthrax protective antigen is a calcium-dependent serine protease
Lisanne Storma, Floris J. Bikkerb, Kamran Nazmib, Albert G. Hulstc, Debora V. der Riet-Van Oeverenc, Enno C.
I. Veermanb, John P. Hays a, and Wendy E. Kamana,b
aDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands; bDepartment
of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The
Netherlands; cDepartment of CBRN Protection, Netherlands Organization for Applied Scientific Research TNO, Rijswijk, The Netherlands
ABSTRACT
Bacillus anthracis secretes a three component exotoxin-complex, which contributes to anthrax
pathogenesis. Formation of this complex starts with the binding of protective antigen (PA) to its
cellular receptor. In this study, we report that PA is a calcium-dependent serine protease and that
the protein potentially uses this proteolytic activity for receptor binding. Additionally our findings
shed new light on previous research describing the inhibition of anthrax toxins and exotoxin
formation. Importantly, inhibition of the proteolytic activity of protective antigen could be a novel
therapeutic strategy in fighting B. anthracis-related infections.
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Introduction
Bacillus anthracis, the causative agent of anthrax, secretes a
three component exotoxin, i.e. lethal toxin, which consists
of the cell binding protective antigen (PA), and the
enzymes edema factor (EF) and lethal factor (LF). This
lethal toxin penetrates host cells and is known to contribute
to anthrax pathogenesis, making it a commonly used target
in the development of vaccines and anti-infectives against
this bacterial pathogen [1,2]. In order to penetrate the host
cell, anthrax lethal toxin utilizes a multi-step mechanism.
First, PA (PA83, 83 kDa) interacts with the host cell surface
via at least two receptors, tumor endothelial marker 8
(TEM8/ANTXR1) and capillary morphogenesis gene 2
(CMG2/ANTXR2) [3,4]. Upon receptor binding PA83 is
cleaved into PA63 (63 kDa) by furin, a calcium-dependent
serine protease, which is produced by the host. PA63 sub-
sequently forms a heptameric structure, known as a ‘pre-
pore’, which interacts with the toxins LF and EF. The entire
receptor-toxin complex is then endocytosed and trans-
ported into low-pH endosomes. Triggered by the acidic
environment a pore forms across the endosomal mem-
brane, after which EF and LF are released into the cytosol
of the host cell [5]. Once present in the cell cytosol, EF and
LF damage the cell in various ways; LF is a zinc-dependent
metalloproteinase that cleaves and inactivates the mitogen-
activated protein kinase (MAPK) kinases 1–4, 6 and 7 [6].
The cleavage events result in inactivation of the MAPK
pathways thereby hampering a variety of cellular responses
including cell division, apoptosis, and survival [7]. EF is a
calmodulin-dependent adenylyl cyclase that elevates intra-
cellular cAMP levels by converting ATP to cAMP, the
classical secondmessenger, thereby causing diverse adverse
side-effects [8]. These processes allow B. anthracis to evade
the hosts` immune system and facilitate proliferation,
resulting in the characteristic disease symptoms of anthrax
that frequently lead to death. In this respect, understanding
the first step in toxin formation, i.e. the interaction between
PA and its receptor, is critical for the development of
effective treatment strategies against B. anthracis related
infections. In previous research, it has been shown that
the interaction between PA83 and its receptors resembles
an pH-dependent α-integrin/ligand binding interaction
[9,10]. Additionally, Bradley and co-workers showed that
EDTA inhibits the binding of PA83 to its receptor, suggest-
ing a role of divalent cations in receptor binding [3]. The
binding-associated regions of both PA83 and its receptors
were identified [11], though the exact mechanism by which
PA83 binds to its receptors remains to be elucidated.
In this study, we demonstrated that PA83 exhibits a
hitherto unknown proteolytic activity which potentially
plays a crucial role in the binding of PA83 to the
ANTXR1 receptor.
Results
PA83 proteolytic activity was characterized by measur-
ing the dose-dependent degradation of the PEK-054
substrate using HEPES-buffered saline as reaction
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buffer (Figure 1(A)). No proteolytic activity could be
detected when the experiment was performed in phos-
phate buffered saline (PBS) buffer (data not shown).
In view of the calcium-chelating properties of phos-
phate ions, it was hypothesized that calcium ions are
required for the proteolytic activity of PA83. This was
corroborated by the finding that EDTA inhibited the
proteolytic activity in a dose-dependent manner
(Figure 1(B)). PA83 activity could be restored by the
addition of Ca2+ and, to a lesser extent, Mg2+ ions
(Figure 1(C)). In contrast, the addition of Zn2+ ions
inhibited the proteolytic activity of PA83 (Figure 1
(D)). Furthermore, we examined the effect of several
(specific) protease inhibitors on PA83 activity. The
addition of the cysteine protease inhibitor NEM
hardly affected protease activity of PA83 (Figure 1
(E)). In contrast, the serine protease inhibitor aproti-
nin at 40 µM virtually completely inhibited PA83 pro-
teolytic activity (Figure 1(F)). Additional experiments
showed that the furin inhibitor D6R was able to inhi-
bit PA83 activity (Figure 2(A)). EGA and MDL281700,
inhibitors of lethal toxin formation, showed no sig-
nificant effect on the proteolytic activity of PA83
(Figure 2(B,C)).
Identity and purity studies of the purchased PA83
protein using LC MS/MS analysis and SDS-PAGE con-
firmed the identity of PA83. The intact, 83 kDa,
protective antigen (coverage 62%) was not contami-
nated with any other proteolytically active proteins
(Figure 3(A and B)). Additionally, inhibition of the
proteolytic activity by a specific antibody for anthrax
protective antigen (α-PA) confirms that the activity
originates from the PA83 protein. No inhibition was
observed upon addition of the antibody control (α-
human IgG) (Figure 4).
To map the cleavage site for PA83, five FRET-based
peptides, covering the full-length of PEK-054 (Figure 5
(A)), were tested in the FRET assay with PA83 and LF,
the protease for which the PEK-054 substrate was ori-
ginally designed. Full-length PEK-054 was hydrolyzed
by both proteins with comparable efficiency (LF:
172.1 ± 5.6 ΔF/min and PA83: 132.9 ± 5.4 ΔF/min).
None of the PEK-054 derivatives was hydrolyzed by LF,
however PA83 was able to hydrolyze derivatives #1, #2
and #5. Peptide #2 (FITC-KKKVLP-KDbc) was prefer-
entially hydrolyzed by PA83 (14.1 ± 0.1 ΔF/min), fol-
lowed by peptide #1 and #5 (6.7 ± 0.1 ΔF/min and
5.1 ± 0.3 ΔF/min respectively). No hydrolysis was
observed with peptide #3 and #4 (Figure 5(A)). A
BLAST search, followed by alignment analysis, revealed
that peptide #2 has a homology region with the
ANTXR1 receptor (Figure 5(B)). This region is present
on the outside of each hexamer of the ANTXR1 recep-
tor protein and is therefore accessible to proteases
Figure 1. Biochemical characterization of PA83 proteolytic activity. PA83 proteolytic activity was determined using FRET-peptide PEK-
054 with varying PA83 concentrations (A). The effect of varying concentrations of (specific) protease inhibitors and metal ions on the
hydrolysis of 16 µM FRET-peptide PEK-054 by PA83 (20 μg/mL). PA83 activity without the addition of inhibitor or metal ions was taken
as the ‘normalized’ (100%) value (B-G). Results are expressed as mean ± SEM (n = 3).
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A B
Accession no. Description Mass Peptides Coverage
WP_000746486.1 protective antigen [Bacillus anthracis] 85811 127 62
XP_004016289.1 hemoglobin subunit beta isoform X1 [Ovis aries] 16073 4 39
XP_014959464.1 hemoglobin subunit alpha-1/2 [Ovis aries] 15007 3 26
NP_001070890.2 hemoglobin subunit alpha [Bos taurus] 15184 3 26
XP_003585623.1 hemoglobin subunit alpha [Bos taurus] 15184 3 26
NP_002265.2 keratin  type I cytoskeletal 13 isoform b [Homo sapiens] 45837 3 7
NP_705694.2 keratin  type I cytoskeletal 13 isoform a [Homo sapiens] 49558 3 7
XP_011539564.1 alpha-amylase 1 isoform X1 [Homo sapiens] 57768 3 6
NP_004029.2 alpha-amylase 1 precursor [Homo sapiens] 57768 3 6
XP_011539565.1 alpha-amylase 1 isoform X1 [Homo sapiens] 57768 3 6
XP_016856547.1 alpha-amylase 1 isoform X1 [Homo sapiens] 57768 3 6
NP_001008222.1 alpha-amylase 1 precursor [Homo sapiens] 57768 3 6
NP_001008220.1 alpha-amylase 1 precursor [Homo sapiens] 57768 3 6
NP_001008219.1 alpha-amylase 1 precursor [Homo sapiens] 57768 3 6
XP_015327143.1 alpha-S2-casein isoform X1 [Bos taurus] 24992 2 10
NP_776953.1 alpha-S2-casein precursor [Bos taurus] 26019 2 10
WP_000808751.1 glycerol phosphate lipoteichoic acid synthase [Bacillus cereus] 74683 2 4
WP_000808758.1 glycerol phosphate lipoteichoic acid synthase [Bacillus anthracis] 74620 2 4
NP_845283.1 lipoteichoic acid synthase [Bacillus anthracis str. Ames] 74578 2 4
WP_000808750.1 glycerol phosphate lipoteichoic acid synthase [Bacillus cereus] 74582 2 4
WP_000808760.1 glycerol phosphate lipoteichoic acid synthase [Bacillus cereus] 74576 2 4
YP_028995.1 lipoteichoic acid synthase [Bacillus anthracis str. Sterne] 74636 2 4
WP_000808762.1 MULTISPECIES: sulfatase [Bacillus] 74636 2 4
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Figure 3. Purity analysis of the PA83 protein used within this study. LC MS/MS analysis of the PA83 protein. Search results of the
Mascot Generic (MGF) files generated against the NCBI database using the Mascot search algorithm (Mascot 2.2.04) are shown. Only
the proteins with ≥ 2 peptide hits are listed (A). SDS-PAGE analysis of the PA83 protein (2 µg) (B).
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Figure 2. Effect of inhibitors of furin protease activity and lethal toxin formation on PA83 proteolytic activity. Varying concentrations
of furin inhibitor D6R (A) and lethal toxin formation inhibitors EGA (B) and MDL28170 (C) were incubated with FRET-peptide PEK-054
and PA83 (20 μg/mL). PA83 activity without the addition of inhibitor was taken as the ‘normalized’ (100%) value. Results are
expressed as mean ± SEM (n = 3).
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(Figure 5(C)). Based on the 4-amino acid sequence
overlap between the ANTXR1 receptor and peptide #2
we designed a 9-amino acid containing FRET-peptide
substrate based on the protein sequence of the
ANTXR1 receptor protein (FITC-LQKVLPGGD-
KDbc (L109-D117)/ANTXR1-peptide). Incubating this
peptide with 20 μg/mL PA83 showed hydrolysis of the
peptide with an average efficiency of 8.1 ± 1.8 ΔF/min
(Figure 5(D)).
Discussion
During a study on LF protease inhibitors we discovered
that PA83, a protein known to be involved in pore
formation during B. anthracis infection, possessed pro-
teolytic activity on the FRET-peptide substrate to detect
LF activity. This proteolytic activity is a feature of PA83
which has not been described before. Characterization
experiments revealed that PA83 proteolytic activity
depends on the presence of divalent cations. Besides,
based on its response to specific protease inhibitors, it
seems most plausible that PA83 belongs to the class of
serine proteases. The strong cation dependency of PA83
explains why its proteolytic activity was not detected
earlier. Besides, the fact that two Ca2+ ions are present
in the quaternary structure of PA83, strengthens the
potential role of Ca2+ in PA83 protease activity [12].
In this respect, Bradley et al showed that binding of
PA83 to its receptor is cation dependent whereas the
binding interaction between the ANTXR1 receptor and
PA83 is impaired in the presence of EDTA [3].
Additionally, Ramey et al showed that binding of
PA83 to the ANTXR1 receptor is dependent on divalent
Figure 4. Specificity testing of the PA83 proteolytic activity.
20 µg/mL PA83 was pre-incubated with 15 µg/mL antibody α-
PA/α-human IgG or PBS (control) for 5 hr. PA83 was measured
using 16 μM FRET-peptide PEK-054. PA83 activity without the
addition of antibodies was taken as the ‘normalized’ (100%)
value. Results are expressed as mean ± SEM (n = 3).
Significance was calculated using an unpaired, two-tailed stu-
dents t-test (* P-value < 0.05).
FITC- -KDbcIQLNAAT
FITC- -KDbcLNAATDK
Peptide Sequence
Proteolytic activity
(ΔF/min)a
LF PA83
PEK-054 172.1  5.6 132.9  5.4 
#1 n.h. 6.7  0.1
#2 n.h. 14.1  0.1
#3 n.h. n.h.
#4 n.h. n.h.
#5 n.h. 5.1  0.3
A
C
FITC-NleKKKKVLPIQLNAATDK-KDbc
FITC- -KDbcNleKKKKVL
FITC- -KDbcKKKVLP
FITC- -KDbcVLPIQLN
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Figure 5. PA83 cleavage specificity and its potential role in ANTXR1 receptor binding. Hydrolysis of FRET-peptide PEK-054 and its
derivatives using 20 µg/mL PA83 or LF
a No hydrolysis: n.h. (A). ANTXR1 sequence alignment was performed using software programs
ClustalW and ESPript 3.0 (Risler matrix, global score of 0.7). Sequence overlap between ANTXR1 and the peptide is depicted in red
(B). Presence of the KVLP-region on the outside of the ANTXR1 protein is marked yellow. The 3D structure of the protein was
generated using the Cn3D 4.3 program (C). Hydrolysis of ANTXR1 peptide (L109-D117) using 20 µg/mL PA83, 20 µg/mL LF or HEPES
buffer (D). Results are expressed as mean ± SEM (n = 3).
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cations, such as Mg2+ and Ca2+ [13]. Based on the
above mentioned studies and our observation that not
only calcium, but also magnesium, was able to restore
PA83 proteolytic activity after inhibition with EDTA,
we provide preliminary evidence that PA83 uses its
proteolytic activity in order to facilitate its binding to
the ANTXR1 receptor. In silico analysis revealed a
sequence overlap between the substrate degraded with
the highest efficiency, peptide #2 (FITC-KKKVLP-
KDbc), and a region in the von Willebrand factor
type A domain (vWA domain) of the ANTXR1 protein.
A FRET-peptide substrate based on the sequence of this
region (ANTXR1-peptide) was successfully degraded by
PA83, again suggesting that PA83 proteolytic activity
plays a role in receptor binding. Further, results pub-
lished by Fu et al showed that the region of the
ANTXR1 receptor that overlaps with the sequence of
peptide #2, interacts with the hydrophobic cleft of
protective antigen [11].
The discovery of PA83 proteolytic activity sheds new
light on previous research involving inhibitors of furin
activity. Within lethal toxin formation this human pro-
tease cleaves PA83 into PA63 and PA20 after which PA63
forms a heptameric pre-pore. Like PA83, furin is a
calcium dependent serine protease whose activity is
inhibited in the presence of Zn2+ ions [14]. Further,
the potential benefits of the use of furin inhibitors in
the treatment of B. anthracis infection has already been
proven in vivo [15–17]. However, the observed thera-
peutic effect of furin inhibitors may not only originate
from furin inhibition but can also be related to inhibi-
tion of PA83 proteolytic activity. Here we show that
there is indeed cross-inhibition of furin inhibitor D6R
with PA83 proteolytic activity. Additionally, inhibitors
of anthrax lethal toxin formation might work via
another mechanism than suggested. For this reason
we examined the effect of two compounds, EGA and
calpain-inhibitor MDL281700, utilized in studies inves-
tigating the inhibition of lethal toxin formation, on the
proteolytic activity of PA83 [18,19]. These compounds
however did not affect PA83 proteolytic activity.
The results described in this study indicate that PA83
possesses proteolytic activity that potentially contributes
to the binding of PA83 to its host cellular receptor.
Additionally, PA83 is able to hydrolyze a protease sub-
strate of which the sequence is based on MAPKK [20],
suggesting that PA83 might possess LF-like activity. Thus
it is hypothesized that by inhibiting the proteolytic activity
of PA83 it may be possible to decrease the pathogenic
potential of B. anthracis. In this light, the substrates
described in this study could potentially help in future
studies aiming to develop PA83 protease inhibitors. For
example, the sequences of the peptide substrates utilized
in this study could possibly be used to develop competi-
tive inhibitors of PA83 protease activity, thereby reducing
the efficiency of PA83 receptor binding or MAPKK degra-
dation. However additional research is needed to precisely
unravel the function of the PA83 proteolytic activity.
In conclusion, to the best of our knowledge, we are the
first who describe proteolytic activity of PA83. This find-
ing may lead to the development of novel therapeutic
strategies against B. anthracis infection and virulence.
Materials and methods
Peptide synthesis
The fluorescence resonance energy transfer (FRET-) pep-
tides used in this study were synthesized by solid-phase
peptide synthesis using Fmoc chemistry and a MilliGen
9050 peptide synthesizer (Milligen-Biosearch). The pep-
tides were flanked at their C-termini with a fluorescent
probe (FITC) and flanked at their N-termini with a lysine
coupled quencher (Dabcyl (Dbc)). FRET-peptides were
purified by reverse-phase high-performance liquid chro-
matography (RP-HPLC). Purity of the FRET-peptides
was confirmed using mass spectrometry, as described
previously [21]. Stock solutions (800 µM) of the
quenched FRET-peptides were prepared in DMSO and
stored at – 20°C.
Protease assay
Proteolytic activity was determined, as described earlier
[22], by incubating 16 µM FRET-peptide with varying
concentrations of PA83 or LF (both List Laboratories)
in HEPES buffer (20 mM HEPES, 0.05% Tween-20, pH
8.2) using blackwell clear bottom 96-well plates
(Corning). Plates were incubated at 37°C for 60 min,
with fluorescence levels being recorded at 2 min inter-
vals using a fluorescence microplate reader (FLUOstar
Galaxy, BMG Laboratories) with an excitation wave-
length of 485 nm and an emission wavelength of
530 nm. Fluorescence values were obtained after cor-
rection against the buffer control. Protease activity was
defined in ΔF per minute (ΔF/min) [23]. An ΔF/min
< 5 was considered as baseline, e.g. no hydrolysis (n.h.).
Cleavage characteristics of PA83
20 µg/mL PA83 was incubated with 16 µM FRET-pep-
tide PEK-054 (FITC-NleKKKKVLPIQLNAATDK-
KDbc) [20] in the presence of varying concentrations
of either protease inhibitors or lethal toxin formation
inhibitors including 4-bromobenzaldehyde N-(2,6-
dimethylphenyl) semicarbazone (EGA), calpain-
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inhibitor MDL281700, furin inhibitor II (hexa-D-argi-
nine (D6R)), EDTA, ZnCl2, N-ethylmaleimide (NEM)
and aprotinin in HEPES buffer (20 mM HEPES, 0.05%
Tween-20, pH 8.2). To study the effect of metal ions on
PA83 proteolytic activity, 20 µg/mL PA83 was incubated
with 16 µM FRET-peptide PEK-054 in HEPES buffer
(20 mM HEPES, 0.05% Tween-20, pH 8.2) supplemen-
ted with 1 mM EDTA. Next, 5 mM CaCl2 or 5 mM
MgCl2 was added to the reaction to restore potential
protease activity. All above mentioned chemicals were
purchased from Sigma Aldrich. Protease activity was
defined as a percentage of the control (PA83 activity
without inhibitor or metal ions).
LC MS/MS
Prior to LC MS/MS analysis 10 µg PA83 was digested
with 0.5 µg trypsin (Difco, BD Biosciences) for 3 hr at
37°C. The trypsinized sample was analyzed by MS/MS
using the data dependent LC-auto MS/MS mode. The
ten most abundant ions (charge states 2+, 3+ and 4+)
in the MS spectrum (300–1300 m/z, 2Hz) of eluted
peptides were selected for data dependent MS/MS ana-
lysis by collision-induced dissociation using nitrogen as
the collision gas. MS/MS scans were acquired over the
mass range 100–2000 m/z (2–10 Hz, depending on
signal intensities). Data files were exported to mzML
format with MSConvert (ProteoWizard 3.0.8764), and
searched with Peaks 7.5 (Bioinformatics Solutions Inc.)
against a custom database consisting of NCBI RefSeq
v77 protein sequences from Homo sapiens, Bos taurus,
Ovis aries and > 400 selected human pathogenic, com-
mensal and near-neighbor bacterial species. Precursor
tolerance was 40 ppm and product ion tolerance was
set to 0.04 Da. Semi-tryptic peptides were allowed with
up to one missed enzymatic cleavage. Oxidation of
methionine was set as variable modification. A PSM
score threshold was selected corresponding to a false
discovery rate of 0.1%, and protein groups required a
minimum of two unique peptides. The resulting FDR at
the peptide and protein level were both < 1%.
SDS-PAGE
PA83 protein (2 µg) was mixed 1:1 with 2x Laemmli
sample buffer (Biorad), incubated for 5 min at 95°C
and loaded onto a 10% SDS-PAGE gel. After electro-
phoresis for 1 hr at 22 mA (max. 160 V) the gel was
stained overnight with PageBlue staining solution
(Fisher Scientific) and washed two times to visualize
bands.
Specificity testing PA83
20 µg/mL PA83 was incubated with 15 µg/mL B.
anthracis protective antigen antibody-[HRP] (α-PA,
Novusbio, BAP0102), 15 µg/mL human IgG antibody-
[HRP] (α-human IgG, Sigma Aldrich, A0170) or PBS
(solvent of the used antibodies) in HEPES buffer for
5 hr at room temperature. Next, 1 µL PEK-054
(800 µM) was added to the reactions and increase in
fluorescence was measured at 37°C for 60 min as
described above.
Abbreviations
PA Protective antigen
LF Lethal factor
EF Edema factor
TEM8 tumor endothelial marker 8
CMG2 capillary morphogenesis gene 2
MAPK mitogen-activated protein kinase
vWA von Willebrand factor type A
D6R hexa-d-arginine
FRET fluorescence resonance energy transfer
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